Based on the KEYNOTE-001/024 study, the US Food and Drug Administration (FDA) announced the approval of pembrolizumab as the first-line treatment for patients with advanced NSCLC with high PD-L1 expression (21). Here, CD274 is linked to non-small cell lung carcinoma.